Amyl Therapeutics is a preclinical-stage biotechnology company developing Pan-Amyloid Immunotherapy (PAI), which targets the conserved amyloid conformation found in all amyloid fibrils. This approach aims to clear amyloid aggregates in late-stage amyloid-mediated diseases and prevent early-stage aggregate formation, addressing the limitations of current treatments that focus solely on amyloid beta.
Funding
$14.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many amyloid-mediated diseases, both neurodegenerative and systemic, lack effective treatments that target the underlying cause: the accumulation of various misfolded protein aggregates known as amyloid fibrils. Current therapies often focus on a single amyloid protein, such as amyloid beta in Alzheimer's disease, which may have limited impact on the broader range of amyloid-related pathologies.
Solution
Amyl Therapeutics is developing Pan-Amyloid Immunotherapy (PAI), a novel approach that targets the conserved amyloid conformation present in all amyloid fibrils, regardless of the specific misfolded protein. This universal treatment aims to clear existing amyloid aggregates in late-stage amyloid-mediated diseases and prevent the formation of new aggregates in early stages. By addressing the common structural element of amyloid fibrils, PAI has the potential to treat a wide range of diseases caused by different misfolded proteins. The therapy is designed to both dissolve early aggregates and clear late-stage aggregates, offering both therapeutic and preventative applications.
Target Audience
The primary target audience includes patients suffering from amyloid-mediated diseases, such as Alzheimer's disease and systemic amyloidosis, as well as healthcare providers and researchers focused on developing effective treatments for these conditions.
Features
- Targets the conserved amyloid conformation found in all amyloid fibrils.
- Designed to clear amyloid aggregates in late-stage amyloid-mediated diseases.
- Aims to inhibit early-stage aggregate formation and dissolve early aggregates.
- Potential application as both a therapeutic and preventative treatment.